JNJ vs TALK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
TALK presents a classic growth-vs-value conflict. While the Piotroski F-Score of 4/9 indicates stable financial health and the company has successfully transitioned to profitability with explosive earnings growth (181% YoY), the valuation is disconnected from deterministic baselines. The stock trades at $5.18, significantly exceeding both the Graham Number ($0.79) and Intrinsic Value ($1.18), suggesting a massive growth premium. Strong liquidity (Current Ratio 6.38) offsets the lack of an Altman Z-Score, but bearish insider activity and a weak technical trend temper the bullish growth narrative.
Compare Another Pair
Related Comparisons
JNJ vs TALK: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Talkspace, Inc. (TALK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.